Back to Cardiology
Cardiologyv2017Evidence-Based

EUROMACS-RHF Score

Determines risk of right ventricular heart failure in patients after left ventricular assist device (LVAD) implantation.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
rhf risk assessment
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The EUROMACS-RHF Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

EUROMACS-RHF Score = (RA/PCWP >0.54 × 2) + (Hemoglobin ≤10 g/dL × 1) + (Multiple IV inotropes × 2.5) + (INTERMACS Class 1-3 × 2) + (Severe RV dysfunction × 2)

Clinical Pearls & Practice Notes

  • Derived from 2,988 adult patients undergoing continuous-flow LVAD implantation
  • Primary population: White (68%) and male (82%)
  • Predicts early (<30 days) severe postoperative right heart failure
  • RHF defined as: short/long-term right-sided circulatory support, continuous inotropic support ≥14 days, or nitric oxide ventilation ≥48 hours
  • Multiple inotropes has greatest weight in predicting post-LVAD RHF
  • C-index: 0.70 in derivation cohort, 0.67 in validation cohort
  • Low risk (0-2 points): 11% RHF incidence
  • High risk (>4 points): 43.1% RHF incidence
  • External validation studies show variable performance
  • Use for preoperative assessment and risk stratification
  • High-risk patients may benefit from biventricular assist device consideration
  • Score should be combined with clinical judgment and other assessment tools
  • Associated with increased ICU stay and reduced 1-year and 2-year survival
  • May guide perioperative monitoring intensity and intervention strategies

Evidence & Literature Citations

  1. Soliman OII, Akin S, Muslem R, Boersma E, Manintveld OC, Krabatsch T, et al. Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk Score. Circulation. 2018 Mar 6;137(9):891-906. doi: 10.1161/CIRCULATIONAHA.117.030543.
  2. Bellavia D, Iacovoni A, Scardulla C, Moja L, Pilato M, Kushwaha SS, et al. Prediction of right heart failure after left ventricular assist device implantation. Eur Heart J Acute Cardiovasc Care. 2017 Dec;6(8):668-676. doi: 10.1177/2048872615612455.
  3. Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, et al. The Society of Thoracic Surgeons Intermacs database annual report: evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant. 2019 Feb;38(2):114-126. doi: 10.1016/j.healun.2018.11.013.

Score Interpretation Ranges

Low Risk0 – 2 pts

Low risk for RHF

Intermediate Risk2.5 – 4 pts

Intermediate risk for RHF

High Risk4.5 – 9.5 pts

High risk for RHF

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.